WCM
DNLI icon

Weld Capital Management’s Denali Therapeutics DNLI Stock Holding History

Weld Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-21,858
Closed -$454K – 812
2019
Q2 		$454K Buy
+21,858
New +$490K 0.08% 415

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Weld Capital Management's DNLI Position: Q3 2019 in Review

Weld Capital Management sold out of Denali Therapeutics (DNLI) in Q3 2019, closing a stake of 21,858 shares — an estimated $454K sold.

Weld Capital Management first reported a position in DNLI in Q2 2019 and held it in 1 quarter. The position peaked at $454K in Q2 2019. 118 funds tracked by Wall St. Rank hold DNLI as of Q3 2019.

  • Weld Capital Management reported no remaining Denali Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Weld Capital Management sold 21,858 Denali Therapeutics shares in Q3 2019, an estimated $454K.
  • Weld Capital Management first reported a position in Denali Therapeutics in Q2 2019 and held it in 1 quarter.
  • Weld Capital Management's Denali Therapeutics position peaked at $454K in Q2 2019.
  • 118 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2019.

Based on Weld Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.